阿达木单抗和英夫利昔单抗治疗化脓性汗腺炎患者的生存情况：一项日常实践队列研究。
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study.
机构信息
Department of Dermatology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Erasmus MC, University Medical Center Rotterdam, Department of Dermatology, Rotterdam, the Netherlands.
出版信息
Br J Dermatol. 2021 Jul;185(1):177-184. doi: 10.1111/bjd.19863. Epub 2021 May 4.
BACKGROUND
Biologics are often required for the treatment of hidradenitis suppurativa (HS). However, data on the drug survival of biologics in daily practice are currently lacking.
OBJECTIVES
To assess the drug survival of antitumour necrosis factor biologics in a daily practice cohort of patients with HS and to identify predictors for drug survival.
METHODS
A retrospective multicentre study was performed in two academic dermatology centres in the Netherlands. Adult patients with HS using biologics between 2008 and 2020 were included. Drug survival was analysed with Kaplan-Meier survival curves and predictors of survival with univariate Cox regression analysis.
RESULTS
The overall drug survival of adalimumab (n = 104) at 12 and 24 months was 56·3% and 30·5%, respectively, which was predominantly determined by infectiveness. Older age (P = 0·02) and longer disease duration (P < 0·01) were associated with longer survival time. For infliximab (n = 44), overall drug survival was 58·3% and 48·6% at 12 and 24 months, respectively, and was predominantly determined by infectiveness and side-effects. Surgery during treatment was associated with a longer survival time (P = 0·01).
CONCLUSIONS
Survival rates were comparable for adalimumab and infliximab at 12 months, and were mainly determined by ineffectiveness. Age, disease duration (adalimumab) and surgery (infliximab) are predictors for longer survival.
背景
生物制剂通常是治疗化脓性汗腺炎（HS）的必需药物。然而，目前缺乏生物制剂在日常实践中的药物生存数据。
目的
评估 HS 患者中使用抗肿瘤坏死因子生物制剂的药物生存情况，并确定药物生存的预测因素。
方法
本研究是在荷兰的两个学术皮肤科中心进行的回顾性多中心研究。纳入 2008 年至 2020 年期间使用生物制剂的成年 HS 患者。使用 Kaplan-Meier 生存曲线分析药物生存情况，并通过单因素 Cox 回归分析确定生存预测因素。
结果
阿达木单抗（n=104）的总体药物生存时间在 12 个月和 24 个月时分别为 56.3%和 30.5%，主要由感染性决定。年龄较大（P=0.02）和疾病持续时间较长（P<0.01）与生存时间延长相关。对于英夫利昔单抗（n=44），总体药物生存时间在 12 个月和 24 个月时分别为 58.3%和 48.6%，主要由感染性和副作用决定。治疗期间的手术与生存时间延长相关（P=0.01）。
结论
阿达木单抗和英夫利昔单抗在 12 个月时的生存率相当，主要由无效性决定。年龄、疾病持续时间（阿达木单抗）和手术（英夫利昔单抗）是生存时间延长的预测因素。
Zotero 插件